Award
NIH Reporter #11184331
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
Recipient
Massachusetts General Hospital
Award Amount
$6,151,947.00
Ceiling
$6,151,947.00
Awarded
August 07, 2025
Identifier
11184331
Award for clinical research on autologous T cell therapy for ALS led by Massachusetts General Hospital with a focus on safety, mechanisms, and efficacy.
Description
This project involves clinical research on autologous T cell therapy for ALS, with a focus on high-risk populations. It is led by Massachusetts General Hospital and sponsored by RAPA Therapeutics, LLC. The project aims to evaluate safety, understand mechanisms, and assess efficacy signals.